Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

RSV vaccines score landmark FDA approvals

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 523-525 (2023)


Updates & Corrections

  • Correction 01 June 2023: Table 1 has been updated to clarify that Arexvy was not developed by GSK for maternal vaccination; the maternal vaccine candidate did not include an adjuvant.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links